TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04122755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA-1000
Description: Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures. Subjects remain in the residential phase through Day21 for safety assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALA-1000
Description: Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures. Subjects remain in the residential phase through Day21 for safety assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine sublingual film
Description: ALA-1000 injection after 7 days of buprenorphine sublingual film dosing. Blood sample for PK analysis are collected before and post sublingual buprenorphine dosing on Day-1
Study: NCT02910843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: • Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Monday through Friday for 5 weeks and 3 days (d1-38) starting on day 1 (daily fraction 1.8 Gy, final dose 50.4 Gy).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: 6-12 weeks (± 1 week) after radio-chemotherapy (RCT) has been completed (42-84 days after last day of RCT).
Study: NCT01740154

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: Undergo TMS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electromyography
Description: Undergo EMG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given PO
Study: NCT03130283

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Hospitalization
Description: Visit every 24 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Hospitalization
Description: No intervention
Study: NCT01844973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: M518101
Description: Proper quantity twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Proper quantity twice a day
Study: NCT03887156

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
Description: Calculation of ex vivo capacities of CD4neg INkT expansion of the peripheral blood from an identified donor for an allograft. Sample is collected before mobilization and the blood culture and analysis using the Predictor test are performed by the central lab.
Study: NCT03293446

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urinary acidification test
Description: Urinary acidification by administration of ammonium chloride (100 mg/kg body weight, given orally) during a single-day hospital admission.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urinary acidification test
Description: Urinary acidification by administration of ammonium chloride (100 mg/kg body weight, given orally) during a single-day hospital admission.
Study: NCT00618852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: The dose of furosemide will be 1 mg/kg by intravenous bolus injection
Study: NCT02215213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplement
Description: comparison of different dosages of vitamin D

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplement
Description: comparison of different dosages of vitamin D

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplement
Description: comparison of different dosages of vitamin D

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplement
Description: comparison of different dosages of vitamin D Supplement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplement
Description: comparison of different dosages of vitamin D Supplement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D supplement
Description: comparison of different dosages of vitamin D Supplement
Study: NCT02575950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO43204

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05235841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Acupressure is a complementary and supportive approach used in symptom management.
Study: NCT02924350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous fluoride
Description: Supervised direct application (Day 0): Participants applied a pea-sized dose of test dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and Home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed each of the 2 qualifying test teeth first, followed by their whole mouth for at least 60 sec. Participants were permitted to rinse with 5 mL tap water (room temperature) for 5 sec. maximum after brushing on supervised brushing (Day 0) and were also permitted to rinse with tap water after brushing on home use (3 days).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate
Description: Supervised direct application (Day 0): participants applied a pea-sized dose of control dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed their whole mouth thoroughly for at least 60 sec. Participants were permitted to rinse with 5mL tap water (room temperature) for 5 sec. maximum after brushing in supervised brushing on Day 0 and were also permitted to rinse with tap water after brushing on home use (3 days).
Study: NCT03836170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: A special catheter was inserted into the peritoneal cavity, and then about 2-5 liters of carbon dioxide was injected. After reaching a certain pressure, four small holes of 0.5-1.5cm were opened in the abdomen to dissect the structure of the triangle of the gallbladder. The gallbladder duct and gallbladder artery were cut off and closed, and then the entire gallbladder was removed.
Study: NCT04755023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide
Description: Chemotherapy (BCNU) will be delivered at Day 1. between day 1 and day 5, temolozomide will be administered . One cycle is planned every 6 weeks until 6 cycles.
Study: NCT03464383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg
Description: Participants will be given escitalopram 10mg by mouth daily and will be followed up with at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral to Psychiatry
Description: Participants randomized to control will have a psychiatry referral order placed by the treating epileptologist under typical care circumstances. This will be an internal or external referral order based on patient preference. If external, the order will be printed along with instructions for the patient to follow to find a provider covered by insurance.

Intervention type: OTHER
Group type: OTHER
Intervention: Survey only
Description: One time survey will be offered to individuals who are found to have anxiety or depression symptoms on screening but who are ineligible for the treatment component of the study, or who decline the treatment study.
Study: NCT01359683

Intervention type: DEVICE
Group type: OTHER
Intervention: Dataq Instruments DI-158
Description: Data Acquisition Device (connects to room instrumentation)
Study: NCT03304613

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management
Description: Already noted.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Resilience through Innovative Self-Management
Description: Already noted.
Study: NCT00990262

Intervention type: RADIATION
Intervention: Cardiac Computed Tomography
Description: 1. Localization of the heart position in a projectional topographic scan of the chest.~2. Determination of contrast agent transit time: 10 ml contrast agent.~3. CT coronary angiography: CT scan in spiral acquisition mode with 330 ms rotation time, 32 x 0.6 mm collimation, a pitch of 2.8 mm/rotation, tube voltage of 120 kVp, and maximum tube current of 850 mA. 80 ml of contrast agent, followed by 40 ml saline solution will be injected at a rate of 4 ml/s. The mean breath hold duration for this acquisition is approximately 13 seconds.
Study: NCT02827578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Tamsulosin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Solifenacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin placebo
Description: Solifenacin placebo
Study: NCT01722864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COV155
Description: COV155 tablets
Study: NCT03747614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorometholone
Description: Fluorometh010neEyeDrops:~Brand names: Allergan Pharmaceuticals Ireland, Serial number: J20130061, NDC 60758-880-05. Tacrolimus Brand names: Senju Pharmaceutical Co., Ltd. Fukusaki Plant Serial number: H20130452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Slit-Lamp Biomicroscopy
Description: A traditional slit lamp (HAAG-STREIT SWISS MADE 900.7.2.34925) was used, and a digital camera (Canon 60D. Canon Inc, Melville, NY) was attached via an inherent camera port. Custom software was used to measure the conjunctival microvascular BFV and vessel diameter using a protocol that has been previously described in detail. At baseline, video clips were recorded on six fields of the bulbar conjunctiva, which was approximately 1 mm from the limbus. During the follow-up visits, attention was given to relocating the vessel segments for these 6 fields.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Slit-Lamp Biomicroscopy
Description: A traditional slit lamp (HAAG-STREIT SWISS MADE 900.7.2.34925) was used, and a digital camera (Canon 60D. Canon Inc, Melville, NY) was attached via an inherent camera port. Custom software was used to measure the conjunctival microvascular BFV and vessel diameter using a protocol that has been previously described in detail. At baseline, video clips were recorded on six fields of the bulbar conjunctiva, which was approximately 1 mm from the limbus. During the follow-up visits, attention was given to relocating the vessel segments for these 6 fields.
Study: NCT00746785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 mg Olanzapine
Description: 2.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5mg Olanzapine
Description: 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03308747

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Instantized Whey Protein Isolate
Description: 0,4 g of whey protein isolate/kg body weight will be ingested as a bolus of 250 ml immediately after the resistance exercise bout.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Instantized Whey Protein Isolate
Description: 0,4 g of whey protein isolate/kg body weight will be ingested as a bolus of 250 ml immediately after the resistance exercise bout.
Study: NCT03200236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Telephone Counseling (8 sessions) with nicotine replacement
Description: Participants are provided up to 8 counseling sessions lasting approximately 20 minutes each and access to 8-weeks of free nicotine replacement patches. A counselor-initiated discussion of screening results will also be included throughout the counseling sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care: Telephone counseling (3 sessions) with nicotine replacement
Description: Participants are provided up to 3 counseling sessions lasting approximately 20 minutes each and access to 2-weeks of free nicotine replacement patches.
Study: NCT03475056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-Marburg vaccine
Description: The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, VRC-MARADC087-00-VP (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-Marburg vaccine
Description: The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, VRC-MARADC087-00-VP (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP).
Study: NCT03948464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Slow release oral morphine (SROM)
Description: Slow release oral morphine is an opioid agonist. Slow release oral morphine will be administered via daily witnessed ingestion at designated community pharmacies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone is an opioid agonist. Methadone will be administered via daily witnessed ingestion at designated community pharmacies.
Study: NCT00618852

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1 mg/kg by intravenous bolus injection
Study: NCT02495818

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Suprascapular Nerve Block Guided by Ultrasound with 5ml lidocaine at 2%.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Saline solution
Description: Suprascapular Nerve Block Guided by Ultrasound with 5ml saline solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Homemade exercises
Description: Codman and Hughston exercises.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Homemade exercises
Description: Codman and Hughston exercises.
Study: NCT04081831

Intervention type: DRUG
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: Follow clinical administration
Study: NCT01458951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: 10 mg oral BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral BID
Study: NCT02535169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education and Coaching Strategy
Description: Utilizing health education and health coaching to intervene with adolescents who are at high risk for type 2 diabetes or prediabetes regarding nutrition and physical activity. A 16-week curriculum will be utilized and phone-based coaching visits will be performed.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dietary consult
Description: A routine clinic-based dietary consult will be performed (approximately 1-hour).
Study: NCT03482895

Intervention type: BIOLOGICAL
Intervention: Blood sampling
Description: Quantitative analysis of enterohormones, citrulline and ApoB48

Intervention type: BIOLOGICAL
Intervention: Feces sampling
Description: Intestinal absorption assessment
Study: NCT02447575

Intervention type: OTHER
Group type: OTHER
Intervention: Education on Use of MDI
Description: After the subject demonstrated the use of MDI with the electronic flowmeter in place, the intervention was provided- a short verbal education to demonstrate the correct use of MDI.
Study: NCT02941354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Each subject will receive a single dose of turoctocog alfa as an intravenous (i.v.) bolus injection of 50 IU/kg.
Study: NCT01244217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine/Allegra (M016455)
Description: Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine/Allegra (M016455)
Description: Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine/Allegra (M016455)
Description: Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral
Study: NCT02968680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Undergo SLNB

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Undergo sonazoid-enhanced ultrasonography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonazoid
Description: Patients receive sonazoid intradermally (ID) and undergo ultrasound imaging.
Study: NCT01326000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: standard iv chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: standard iv chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: standard iv chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: standard iv chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5083945
Description: 1400 mg iv on Day 1 and Day 8, and every 2 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5083945
Description: 1400 mg iv on Day 1 and Day 8, and every 2 weeks thereafter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: 400 mg/m2 iv on Day 1, followed by 250 mg/m2 iv every week
Study: NCT04309903

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Both groups received for 3 sessions per week, a total of 5 weeks. Home exercises were performed by the patient for 30 minutes at home.In home exercises active ROM for warm-up (5 min), passive stretchening (5 min), strengthening exercises (10 min), proprioceptive and balance exercises (10 min). In manual therapy group, myofascial release techniques (MRT) and Kalternborn mobilization techniques lasted about one hour. In MRT, each manuever was applied for 2 mins and 3 times. The superficial strokes were performed, assisted by slight movements of joints. MRT to posterior capsule of the knee, ligaments, iliotibial tractus, plantar fascia, metatarsal, tarsals, and toes. Kalterborb mobilization tecnqiues; posterior gliding for restricted knee flexion, anterior gliding for restricted knee extension,talocrural posteior gliding for dorsal flexion, talocrural anterior gliding for plantar flexion.3 \* 10 repetitions, 20 sec of per reps and 10 sec of interval.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Both groups received for 3 sessions per week, a total of 5 weeks. Home exercises were performed by the patient for 30 minutes at home.In home exercises active ROM for warm-up (5 min), passive stretchening (5 min), strengthening exercises (10 min), proprioceptive and balance exercises (10 min). In manual therapy group, myofascial release techniques (MRT) and Kalternborn mobilization techniques lasted about one hour. In MRT, each manuever was applied for 2 mins and 3 times. The superficial strokes were performed, assisted by slight movements of joints. MRT to posterior capsule of the knee, ligaments, iliotibial tractus, plantar fascia, metatarsal, tarsals, and toes. Kalterborb mobilization tecnqiues; posterior gliding for restricted knee flexion, anterior gliding for restricted knee extension,talocrural posteior gliding for dorsal flexion, talocrural anterior gliding for plantar flexion.3 \* 10 repetitions, 20 sec of per reps and 10 sec of interval.
Study: NCT01718431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: test meal
Study: NCT05740345

Intervention type: DRUG
Intervention: Metformin
Description: Metformin
Study: NCT00089635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered by intravenous infusion
Study: NCT02787057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin
Description: IP vancomycin 1g every 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Description: IP vancomycin 1g every 5 days
Study: NCT01718431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reference meal
Study: NCT01171183

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: controlled release carvedilol
Description: carvedilol (Coreg CR) 80 mg/day in once daily dosing for 12 weeks followed by a 2-week taper

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04260464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: A single dose of 30 mg PF-06700841 will be administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: A single dose of 30 mg PF-06700841 will be administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: A single dose of 30 mg PF-06700841 will be administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: A single dose of 30 mg PF-06700841 will be administered on Day 1
Study: NCT00522717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Subjects receive CBT in the home for 8 weeks with blood draws every other week during therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Subjects receive Usual Care for 8 weeks followed by CBT
Study: NCT04578587

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MicroFET 2
Description: Lumbar Flexor and Extensor Strength Measurement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MicroFET 2
Description: Lumbar Flexor and Extensor Strength Measurement
Study: NCT01726049

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks